Activity Date: 10/06/2022
Date: Thursday, 10/06/2022
Time: 12:00 PM
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.
Despite advancements in new treatments for major depressive disorder, individual therapies and accepted early treatment strategies continue to be associated with remission rates that fail to meet the desired outcomes. Treatments have expanded beyond the traditional pharmacologic options of tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs) to include targeted receptor effects at both serotonergic and noradrenergic receptors, including receptor modulation. While both “old” and “new” treatments are effective and demonstrate response, a large number of those treated will continue to demonstrate a lack of optimal response or treatment resistance.
Data from the landmark STAR*D trials taught that only modest rates of remission were able to be achieved with traditional treatments, switch, and augmentation strategies that were commonly employed. Since the STAR*D studies, a number of new treatments have been developed and marketed along with the expanded use of second-generation antipsychotics in patients not achieving an optimal positive response to single agent therapy. In this program, we will review the progression of antidepressant development, traditional treatment approaches, and new considerations on how best to help patients achieve remission.
To receive ACPE credit for this session, you must:
Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Christoph U. Correll, MD
Steven C. Stoner, PharmD, BCPP
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Dr. Correll: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Lurasidone for MDD with mixed features Dr. Stoner: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Adjunctive therapies for depression including levothyroxine, lithium, unapproved second generation antipsychotics.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck